Madrigal Pharmaceuticals, Inc. Share Price
Stocks
MDGL
US5588681057
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 538.80 USD | -2.26% |
|
-1.46% | -7.48% |
| 27/07 | Wells Fargo Initiates Madrigal Pharmaceuticals at Overweight With $685 Price Target | MT |
| 22/07 | BofA Securities Adjusts Price Target on Madrigal Pharmaceuticals to $553 From $542 | MT |
| Market Cap | 1.24TCr 1.09TCr 1.02TCr 933.74Cr 1.75TCr 1,18700Cr 1.78TCr 12TCr 4.71TCr 59TCr 4.66TCr 4.56TCr 2,03400Cr | P/E 2026 * |
-76.6x | P/E 2027 * | 61.9x |
|---|---|---|---|---|---|
| Enterprise Value | 1.19TCr 1.04TCr 973.1Cr 895.02Cr 1.68TCr 1,13800Cr 1.71TCr 12TCr 4.52TCr 56TCr 4.47TCr 4.37TCr 1,94900Cr | EV / Sales 2026 * |
7.92x | EV / Sales 2027 * | 5.22x |
| Free-Float |
94.11% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Madrigal Pharmaceuticals, Inc.
| 1 day | -2.26% | ||
| 1 week | -1.46% | ||
| Current month | +0.34% | ||
| 1 month | +5.10% | ||
| 3 months | +4.28% | ||
| 6 months | +8.51% | ||
| Current year | -7.48% |
| 1 week | 526.6 |  | 566.18 |
| 1 month | 507.6 | | 569.44 |
| Current year | 416.21 | | 598.79 |
| 1 year | 286.44 | | 615 |
| 3 years | 119.76 | | 615 |
| 5 years | 52.33 | | 615 |
| 10 years | 6.6 | | 615 |
| Manager | Title | Age | Since |
|---|---|---|---|
William Sibold
CEO | Chief Executive Officer | 59 | 08/09/2023 |
Mardi Dier
DFI | Director of Finance/CFO | 62 | 11/03/2024 |
David Soergel
CTO | Chief Tech/Sci/R&D Officer | 58 | 21/04/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Rebecca Taub
BRD | Director/Board Member | 74 | 01/07/2016 |
Richard Levy
BRD | Director/Board Member | 68 | 11/08/2016 |
James Daly
BRD | Director/Board Member | 64 | 27/06/2019 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 20/07/26 | Sell | Chief Executive Officer | -2,500 | 0.0108% | ||
| 17/06/26 | Free | Director | 1,220 | 0.0053% | ||
| 17/06/26 | Baker Bros. Advisors LP
| Free | Company | 4,880 | 0.0212% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.26% | -1.46% | +83.17% | +162.18% | 1.24TCr | |
| -2.25% | +1.55% | +50.84% | +70.04% | 5.5TCr | |
| -1.32% | -2.71% | +34.27% | +77.57% | 5.42TCr | |
| +1.49% | +0.13% | -18.03% | -13.94% | 2.34TCr | |
| -0.57% | -4.13% | +2.34% | +387.73% | 2.26TCr | |
| +1.97% | +1.18% | +16.96% | -10.88% | 2.02TCr | |
| 0.00% | +3.00% | +27.41% | -29.52% | 1.79TCr | |
| -4.11% | -5.45% | +24.00% | +546.99% | 1.55TCr | |
| -6.69% | -5.11% | +169.13% | +304.89% | 1.42TCr | |
| +1.25% | +0.69% | +27.30% | +184.69% | 1.42TCr | |
| Average | -1.24% | -0.31% | +41.74% | +167.97% | 2.5TCr | |
| Weighted average by Cap. | -1.21% | -0.35% | +37.32% | +132.96% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 150.31Cr 131.91Cr 122.84Cr 112.98Cr 211.8Cr 14TCr 215.43Cr 1.46TCr 570.42Cr 7.12TCr 564.3Cr 552.11Cr 25TCr | 217.45Cr 190.83Cr 177.71Cr 163.45Cr 306.39Cr 21TCr 311.65Cr 2.11TCr 825.2Cr 10TCr 816.35Cr 798.71Cr 36TCr |
| Net income | -20Cr -17Cr -16Cr -15Cr -28Cr -1.88TCr -28Cr -190.86Cr -75Cr -932.72Cr -74Cr -72Cr -3.22TCr | 27Cr 24Cr 22Cr 20Cr 38Cr 2.57TCr 39Cr 261.07Cr 102.19Cr 1.28TCr 101.09Cr 99Cr 4.41TCr |
| Net Debt | -52Cr -45Cr -42Cr -39Cr -73Cr -4.92TCr -74Cr -499.46Cr -195.49Cr -2.44TCr -193.4Cr -189.22Cr -8.43TCr | -107.6Cr -94Cr -88Cr -81Cr -151.61Cr -10TCr -154.21Cr -1.04TCr -408.33Cr -5.1TCr -403.96Cr -395.23Cr -18TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 28/26/28 | $538.80 | -2.26% | 2,18,771 |
| 27/26/27 | $551.25 | +1.24% | 2,68,615 |
| 24/26/24 | $544.51 | +0.21% | 1,47,390 |
| 23/26/23 | $543.35 | +1.06% | 1,60,514 |
| 22/26/22 | $537.65 | -1.67% | 3,10,899 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- MDGL Stock
Select your edition
All financial news and data tailored to specific country editions
